Clinical Trial Update: Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial investigating olaparib for metastatic biliary tract cancer with aberrant DNA repair gene mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Adenocarcinoma
• Biliary Tract Cancer
• Biliary Tract Carcinoma

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation | Phase 2 | Status: UNKNOWN